Intrinsic value of Masimo - MASI

Previous Close

$102.34

  Intrinsic Value

$173.63

stock screener

  Rating & Target

str. buy

+70%

Previous close

$102.34

 
Intrinsic value

$173.63

 
Up/down potential

+70%

 
Rating

str. buy

We calculate the intrinsic value of MASI stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 5.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  14.90
  13.91
  13.02
  12.22
  11.50
  10.85
  10.26
  9.74
  9.26
  8.84
  8.45
  8.11
  7.80
  7.52
  7.26
  7.04
  6.83
  6.65
  6.49
  6.34
  6.20
  6.08
  5.97
  5.88
  5.79
  5.71
  5.64
  5.58
  5.52
  5.47
Revenue, $m
  917
  1,044
  1,180
  1,325
  1,477
  1,637
  1,805
  1,981
  2,164
  2,355
  2,555
  2,762
  2,977
  3,201
  3,433
  3,675
  3,926
  4,187
  4,459
  4,741
  5,035
  5,342
  5,661
  5,994
  6,341
  6,703
  7,081
  7,476
  7,888
  8,319
Variable operating expenses, $m
  361
  411
  464
  520
  579
  642
  707
  775
  847
  921
  994
  1,074
  1,158
  1,245
  1,335
  1,429
  1,527
  1,629
  1,734
  1,844
  1,959
  2,078
  2,202
  2,331
  2,466
  2,607
  2,754
  2,908
  3,068
  3,236
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  361
  411
  464
  520
  579
  642
  707
  775
  847
  921
  994
  1,074
  1,158
  1,245
  1,335
  1,429
  1,527
  1,629
  1,734
  1,844
  1,959
  2,078
  2,202
  2,331
  2,466
  2,607
  2,754
  2,908
  3,068
  3,236
Operating income, $m
  555
  633
  716
  805
  898
  995
  1,098
  1,205
  1,318
  1,434
  1,561
  1,687
  1,819
  1,956
  2,098
  2,245
  2,399
  2,558
  2,724
  2,897
  3,077
  3,264
  3,459
  3,662
  3,874
  4,095
  4,326
  4,568
  4,820
  5,083
EBITDA, $m
  583
  664
  751
  842
  939
  1,041
  1,148
  1,260
  1,376
  1,498
  1,624
  1,756
  1,893
  2,035
  2,183
  2,337
  2,497
  2,663
  2,835
  3,015
  3,202
  3,397
  3,600
  3,811
  4,032
  4,262
  4,503
  4,754
  5,016
  5,290
Interest expense (income), $m
  4
  0
  2
  3
  5
  7
  9
  12
  14
  16
  19
  21
  24
  27
  30
  33
  36
  40
  43
  47
  50
  54
  58
  62
  67
  71
  76
  81
  86
  92
  97
Earnings before tax, $m
  555
  632
  713
  799
  890
  986
  1,087
  1,192
  1,301
  1,416
  1,539
  1,663
  1,792
  1,926
  2,065
  2,209
  2,359
  2,515
  2,678
  2,847
  3,023
  3,206
  3,396
  3,595
  3,803
  4,019
  4,245
  4,481
  4,728
  4,986
Tax expense, $m
  150
  171
  193
  216
  240
  266
  293
  322
  351
  382
  416
  449
  484
  520
  557
  596
  637
  679
  723
  769
  816
  866
  917
  971
  1,027
  1,085
  1,146
  1,210
  1,277
  1,346
Net income, $m
  405
  461
  521
  584
  650
  720
  793
  870
  950
  1,033
  1,124
  1,214
  1,308
  1,406
  1,507
  1,613
  1,722
  1,836
  1,955
  2,078
  2,206
  2,340
  2,479
  2,625
  2,776
  2,934
  3,099
  3,271
  3,451
  3,640

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  858
  977
  1,104
  1,239
  1,382
  1,531
  1,689
  1,853
  2,025
  2,203
  2,390
  2,583
  2,785
  2,994
  3,212
  3,438
  3,673
  3,917
  4,171
  4,435
  4,710
  4,997
  5,296
  5,607
  5,931
  6,270
  6,624
  6,993
  7,379
  7,782
Adjusted assets (=assets-cash), $m
  858
  977
  1,104
  1,239
  1,382
  1,531
  1,689
  1,853
  2,025
  2,203
  2,390
  2,583
  2,785
  2,994
  3,212
  3,438
  3,673
  3,917
  4,171
  4,435
  4,710
  4,997
  5,296
  5,607
  5,931
  6,270
  6,624
  6,993
  7,379
  7,782
Revenue / Adjusted assets
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
  1.069
Average production assets, $m
  228
  260
  294
  330
  368
  408
  449
  493
  539
  587
  636
  688
  741
  797
  855
  915
  978
  1,043
  1,110
  1,181
  1,254
  1,330
  1,410
  1,492
  1,579
  1,669
  1,763
  1,861
  1,964
  2,071
Working capital, $m
  72
  81
  92
  103
  115
  128
  141
  155
  169
  184
  199
  215
  232
  250
  268
  287
  306
  327
  348
  370
  393
  417
  442
  468
  495
  523
  552
  583
  615
  649
Total debt, $m
  30
  63
  97
  134
  173
  213
  256
  301
  347
  396
  447
  499
  554
  611
  670
  732
  796
  862
  931
  1,003
  1,078
  1,156
  1,237
  1,322
  1,410
  1,502
  1,598
  1,699
  1,804
  1,914
Total liabilities, $m
  233
  266
  300
  337
  376
  417
  459
  504
  551
  599
  650
  703
  757
  814
  874
  935
  999
  1,065
  1,134
  1,206
  1,281
  1,359
  1,440
  1,525
  1,613
  1,705
  1,802
  1,902
  2,007
  2,117
Total equity, $m
  624
  711
  804
  902
  1,006
  1,115
  1,229
  1,349
  1,474
  1,604
  1,740
  1,881
  2,027
  2,180
  2,338
  2,503
  2,674
  2,851
  3,036
  3,229
  3,429
  3,638
  3,855
  4,082
  4,318
  4,565
  4,822
  5,091
  5,372
  5,665
Total liabilities and equity, $m
  857
  977
  1,104
  1,239
  1,382
  1,532
  1,688
  1,853
  2,025
  2,203
  2,390
  2,584
  2,784
  2,994
  3,212
  3,438
  3,673
  3,916
  4,170
  4,435
  4,710
  4,997
  5,295
  5,607
  5,931
  6,270
  6,624
  6,993
  7,379
  7,782
Debt-to-equity ratio
  0.050
  0.090
  0.120
  0.150
  0.170
  0.190
  0.210
  0.220
  0.240
  0.250
  0.260
  0.270
  0.270
  0.280
  0.290
  0.290
  0.300
  0.300
  0.310
  0.310
  0.310
  0.320
  0.320
  0.320
  0.330
  0.330
  0.330
  0.330
  0.340
  0.340
Adjusted equity ratio
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728
  0.728

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  405
  461
  521
  584
  650
  720
  793
  870
  950
  1,033
  1,124
  1,214
  1,308
  1,406
  1,507
  1,613
  1,722
  1,836
  1,955
  2,078
  2,206
  2,340
  2,479
  2,625
  2,776
  2,934
  3,099
  3,271
  3,451
  3,640
Depreciation, amort., depletion, $m
  28
  31
  34
  38
  42
  46
  50
  54
  59
  63
  64
  69
  74
  80
  85
  92
  98
  104
  111
  118
  125
  133
  141
  149
  158
  167
  176
  186
  196
  207
Funds from operations, $m
  433
  492
  555
  621
  692
  765
  843
  924
  1,009
  1,097
  1,187
  1,283
  1,382
  1,485
  1,593
  1,704
  1,820
  1,941
  2,066
  2,196
  2,332
  2,473
  2,620
  2,774
  2,934
  3,101
  3,275
  3,458
  3,648
  3,847
Change in working capital, $m
  9
  10
  11
  11
  12
  12
  13
  14
  14
  15
  16
  16
  17
  17
  18
  19
  20
  20
  21
  22
  23
  24
  25
  26
  27
  28
  29
  31
  32
  34
Cash from operations, $m
  424
  482
  544
  610
  680
  753
  830
  910
  994
  1,082
  1,172
  1,267
  1,365
  1,468
  1,575
  1,685
  1,800
  1,920
  2,045
  2,174
  2,309
  2,449
  2,595
  2,748
  2,907
  3,073
  3,246
  3,427
  3,616
  3,813
Maintenance CAPEX, $m
  -20
  -23
  -26
  -29
  -33
  -37
  -41
  -45
  -49
  -54
  -59
  -64
  -69
  -74
  -80
  -85
  -92
  -98
  -104
  -111
  -118
  -125
  -133
  -141
  -149
  -158
  -167
  -176
  -186
  -196
New CAPEX, $m
  -30
  -32
  -34
  -36
  -38
  -40
  -42
  -44
  -46
  -48
  -50
  -52
  -54
  -56
  -58
  -60
  -63
  -65
  -68
  -70
  -73
  -76
  -79
  -83
  -86
  -90
  -94
  -98
  -103
  -107
Cash from investing activities, $m
  -50
  -55
  -60
  -65
  -71
  -77
  -83
  -89
  -95
  -102
  -109
  -116
  -123
  -130
  -138
  -145
  -155
  -163
  -172
  -181
  -191
  -201
  -212
  -224
  -235
  -248
  -261
  -274
  -289
  -303
Free cash flow, $m
  374
  427
  484
  545
  609
  676
  747
  822
  899
  980
  1,064
  1,152
  1,243
  1,338
  1,437
  1,540
  1,646
  1,757
  1,873
  1,993
  2,118
  2,248
  2,383
  2,524
  2,671
  2,825
  2,985
  3,152
  3,327
  3,509
Issuance/(repayment) of debt, $m
  30
  32
  35
  37
  39
  41
  43
  45
  47
  49
  51
  53
  55
  57
  59
  61
  64
  66
  69
  72
  75
  78
  81
  85
  88
  92
  96
  100
  105
  110
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  30
  32
  35
  37
  39
  41
  43
  45
  47
  49
  51
  53
  55
  57
  59
  61
  64
  66
  69
  72
  75
  78
  81
  85
  88
  92
  96
  100
  105
  110
Total cash flow (excl. dividends), $m
  404
  460
  519
  581
  648
  717
  790
  866
  946
  1,029
  1,114
  1,204
  1,298
  1,395
  1,496
  1,601
  1,710
  1,824
  1,942
  2,065
  2,192
  2,326
  2,464
  2,609
  2,760
  2,917
  3,081
  3,253
  3,432
  3,619
Retained Cash Flow (-), $m
  -81
  -87
  -93
  -98
  -104
  -109
  -114
  -120
  -125
  -130
  -136
  -141
  -147
  -152
  -158
  -165
  -171
  -178
  -185
  -192
  -200
  -209
  -217
  -227
  -236
  -247
  -257
  -269
  -281
  -294
Prev. year cash balance distribution, $m
  164
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  18
  20
  23
  26
  29
  32
  36
  40
  44
  48
  52
  56
  61
  65
  70
  76
  81
  86
  92
  98
  104
  111
  118
  125
  132
  139
  147
  156
  164
  174
Cash available for distribution, $m
  487
  373
  426
  483
  544
  608
  676
  747
  821
  899
  979
  1,063
  1,151
  1,243
  1,338
  1,437
  1,539
  1,646
  1,757
  1,872
  1,992
  2,117
  2,247
  2,382
  2,523
  2,670
  2,824
  2,984
  3,151
  3,325
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  467
  342
  371
  398
  422
  441
  456
  467
  472
  471
  465
  454
  438
  417
  393
  365
  335
  303
  271
  238
  206
  176
  147
  121
  98
  78
  61
  46
  34
  25
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company's business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include non-invasive monitoring of blood constituents with an optical signature, optical organ oximetry monitoring, electrical, brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, the Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor, and the Radius-7 wearable wireless patient monitor. It offers Patient SafetyNet remote patient surveillance monitoring system, which allows patients to be monitored through a personal computer-based monitor or by care providers through their pagers, voice-over-Internet Protocol (IP) phones or smartphones.

FINANCIAL RATIOS  of  Masimo (MASI)

Valuation Ratios
P/E Ratio 17.1
Price to Sales 7.4
Price to Book 9.2
Price to Tangible Book
Price to Cash Flow 12.3
Price to Free Cash Flow 13.1
Growth Rates
Sales Growth Rate 10.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -56.4%
Cap. Spend. - 3 Yr. Gr. Rate 13%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 106
Management Effectiveness
Return On Assets 42.7%
Ret/ On Assets - 3 Yr. Avg. 23.9%
Return On Total Capital 59%
Ret/ On T. Cap. - 3 Yr. Avg. 32.3%
Return On Equity 72.1%
Return On Equity - 3 Yr. Avg. 41.3%
Asset Turnover 1
Profitability Ratios
Gross Margin 66.8%
Gross Margin - 3 Yr. Avg. 66.2%
EBITDA Margin 63.2%
EBITDA Margin - 3 Yr. Avg. 34.7%
Operating Margin 60.6%
Oper. Margin - 3 Yr. Avg. 32.4%
Pre-Tax Margin 60.1%
Pre-Tax Margin - 3 Yr. Avg. 32%
Net Profit Margin 43.3%
Net Profit Margin - 3 Yr. Avg. 23%
Effective Tax Rate 28%
Eff/ Tax Rate - 3 Yr. Avg. 28.3%
Payout Ratio 0%

MASI stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MASI stock intrinsic value calculation we used $798 million for the last fiscal year's total revenue generated by Masimo. The default revenue input number comes from 2017 income statement of Masimo. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MASI stock valuation model: a) initial revenue growth rate of 14.9% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for MASI is calculated based on our internal credit rating of Masimo, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Masimo.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MASI stock the variable cost ratio is equal to 39.5%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for MASI stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Masimo.

Corporate tax rate of 27% is the nominal tax rate for Masimo. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MASI stock is equal to 2.2%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MASI are equal to 24.9%.

Life of production assets of 10 years is the average useful life of capital assets used in Masimo operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MASI is equal to 7.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $707 million for Masimo - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 52 million for Masimo is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Masimo at the current share price and the inputted number of shares is $5.3 billion.

RELATED COMPANIES Price Int.Val. Rating
CASM CAS Medical Sy 1.96 0.02  str.sell
OMI Owens&Minor 17.45 28.37  str.buy
RMD ResMed 109.33 53.87  sell
BABY Natus Medical 32.75 24.01  sell
BDX Becton Dickins 247.03 144.47  sell
AHPI Allied Healthc 2.50 1.00  str.sell
OSIS OSI Systems 78.13 26.94  str.sell

COMPANY NEWS

▶ The 6 Stocks on the MFM Team's Radar This Week   [Jun-19-18 07:20AM  Motley Fool]
▶ Masimo and PositiveID Announce the U.S. Release of TIR-1   [Jun-18-18 08:00AM  Business Wire]
▶ 3 Top Healthcare Stocks to Buy in May   [May-15-18 06:00AM  Motley Fool]
▶ Masimo: 1Q Earnings Snapshot   [May-02-18 06:17PM  Associated Press]
▶ Edited Transcript of MASI presentation 7-Mar-17 2:50pm GMT   [Apr-10-18 10:59AM  Thomson Reuters StreetEvents]
▶ Masimo Announces UniView   [08:00AM  Business Wire]
▶ Masimo Corporation (NASDAQ:MASI): Will The Growth Last?   [Mar-30-18 08:15AM  Simply Wall St.]
▶ Masimo to Present at Barclays Global Healthcare Conference   [Mar-07-18 09:00AM  Business Wire]
▶ Masimo Announces Replica   [Mar-06-18 08:00AM  Business Wire]
▶ Masimo beats Street 4Q forecasts   [Feb-27-18 06:36PM  Associated Press]
▶ 6 Companies Growing Revenue and Earnings   [Jan-17-18 03:42PM  GuruFocus.com]
▶ 3 Healthcare Stocks to Buy for 2018   [08:34AM  Motley Fool]
▶ ETFs with exposure to Masimo Corp. : December 27, 2017   [Dec-27-17 11:30AM  Capital Cube]
▶ ETFs with exposure to Masimo Corp. : December 14, 2017   [Dec-14-17 01:47PM  Capital Cube]
▶ ETFs with exposure to Masimo Corp. : November 17, 2017   [Nov-17-17 12:21PM  Capital Cube]
▶ Masimo Supports World Pneumonia Day Efforts   [Nov-13-17 08:00AM  Business Wire]
▶ Masimo Earns IBD Rating Upgrade   [03:00AM  Investor's Business Daily]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.